Things
Public call for the selection of project proposals to be financed within the research program of the innovation ecosystem "THE - TUSCANY HEALTH ECOSYSTEM", drawing on the resources of the national plan for recovery and resilience (PNRR), mission 4 " education and research” – component 2 “from research to business” – investment 1.5 – creation and strengthening of “innovation ecosystems for sustainability”, creation of “territorial R&D leaders”, financed by the European Union – EXTGENERATIONEU, issued from Spoke 6 “PRECISION MEDICINE & PERSONALIZED HEALTHCARE”.
Who is it aimed at?
The following can request the benefits: − Micro, Small and Medium-sized enterprises (MSMEs), external to the THE Ecosystem, which compete in single or collaborative mode with other enterprises, having the dimensional parameters referred to in Annex I of REG (EC) n . 800/2008 of the Commission of 6 August 2008 (General Block Exemption Regulation) in OJEU L 214 of 9.8.2008; − Large Enterprises (GI), external to the THE Ecosystem, in collaborative mode provided that the requirement of collaboration with at least one MSME; can support a maximum of 70% of the total eligible cost of the project; − research organizations (Od R), external to the THE Ecosystem, in collaborative mode, as defined pursuant to point 1.3 letter (ff) of the new RSI regulation of referred to in communication C(2022) 7388 of 19 October 2022, both public and private.
What does it predict
The call intends to support research to − develop advanced biomarkers (for example immunological, molecular, etc.) to improve patient stratification; − generate personalized and advanced approaches for the treatment and management of chronic patients; − exploit the artificial intelligence and technologies for omics and computational biology; − building personalized medical devices that can help monitor and treat patients; The lines of research are: 1 – Characterization of biomarkers to improve the management of patients with glioblastoma; 2 – Molecular characterization of primary and acquired chemo-resistance in patients with acute leukemia; 3 – Lipid cargo of Evs from hypoxic tumor cells; 4 – Development of new kits based on advanced technologies;5 – Identification of expression-based biomarkers associated with prognosis for the management of cancer patients;6 – Drug design, discovery and development for innovative treatments in precision medicine;7 – Application of in silico methods for the development of cancer biomarkers;8 – In silico drug selection targeting the heterogeneity of cancer patients with prediction of clinical outcome;9 – Development of algorithmic methods for the analysis of genomic and exomic sequences for precision medicine purposes;10 – Virtual screening methods for anti-inflammatory chemotherapeutics;11 – IT support for tool development;12 – Biochemical support for molecule testing;13 – Analysis of transcriptomic signatures;14 – Monitoring systems of mental health;15 – Energy metabolism measurement systems;16 – Immunity and microenvironment;17 – Biomarkers for early diagnosis, prognosis and response to treatment;18 – Endometrial biomarkers;19 – Biomarkers in the context of lung diseases; 20 – Automatic identification of amyloid plaques in Alzheimer patients; 21 – Stratification of multiple sclerosis patients using multiomics artificial intelligence techniques.
